

PanGenomic Health Announces Intention to Reprice Outstanding Warrants

Vancouver, British Columbia, Canada, January 9, 2025 – PanGenomic Health Inc. (“PanGenomic” or the “Company”) (CSE: NARA), announced that it intends to amend the exercise price of a total of 4,300,464 share purchase warrants (the “**Warrants**”) having a current exercise price of \$0.50 per share (on a post-consolidation basis) to \$0.17 per share (the “**Warrant Repricing**”). Effectiveness of the proposed Warrant Repricing is subject to the unanimous approval of the registered holders of the Warrants.

The Warrants were issued by the Company on or about May 27, 2024, with each Warrant exercisable to acquire one Class A Common Share in the capital of the Company (the “**Shares**”) for a period expiring on May 27, 2026. The expiry date of the Warrants after the Warrant Repricing will remain unchanged. However, if, at any time after the Warrant Repricing becomes effective, the closing price of the Shares, as quoted by the Canadian Securities Exchange (the “**CSE**”), is equal to or greater than \$0.23 per Share for 10 consecutive trading days, the expiration date of the Warrants will automatically be accelerated to the date that is 30 calendar days after the date of such 10 consecutive trading day period.

Under the policies of the CSE, the proposed Warrant Repricing is subject to the unanimous consent of the registered holders of the outstanding Warrants. If the Warrant Repricing is approved by holders of the Warrants, it is expected that replacement Warrant certificates will not be issued and that notice of the amendment will be sent to holders of the Warrants. None of the Warrants are held by “related parties” of the Company.

About PanGenomic Health Inc.

PanGenomic Health Inc. is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company’s initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic’s mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

For more information, please contact:

Jerry Lai, Investor Relations
PanGenomic Health Inc.
+1 778 743 4642
ir@pangenomic.com

This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of

factors and risks including various risk factors discussed in PanGenomic Health's disclosure documents which can be found under PanGenomic Health's profile on www.sedarplus.ca.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.